A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry
0301 basic medicine
0303 health sciences
03 medical and health sciences
Cinnamomum zeylanicum
Dose-Response Relationship, Drug
Biflavonoids
Humans
Proanthocyanidins
Hepacivirus
Hepatitis C, Chronic
Antiviral Agents
Catechin
3. Good health
DOI:
10.1007/s12072-017-9809-y
Publication Date:
2017-07-11T08:13:44Z
AUTHORS (8)
ABSTRACT
Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Although direct-acting antivirals can cure the large majority of treated patients, important limitations remain, including treatment failure and high costs precluding access to therapy in resource-limited settings. We report herein the anti-HCV effects of IND02, a procyanidin type A molecule, isolated and characterized from cinnamon.Using cellculture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and subgenomic replicons, we demonstrated that IND02 markedly and dose-dependently inhibited HCV cell entry. Kinetic assays demonstrated that IND02 inhibits HCV entry most likely at a postbinding step. Experiments performed using primary human hepatocytes confirmed inhibition of HCV entry by IND02, demonstrating the functional impact in the most physiological cell-based system for studying HCV-host interactions.The natural compound IND02 exhibits potent HCV cell entry inhibition and provides a novel perspective for development of a low-cost antiviral for treatment of HCV infection.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (15)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....